Tayeh Malatee, Watanapokasin Ramida
Department of Medical Technology, School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80160, Thailand.
Department of Biochemistry, Faculty of Medicine, Srinakharinwirot University, Bangkok 10110, Thailand.
Evid Based Complement Alternat Med. 2020 Jul 27;2020:8180261. doi: 10.1155/2020/8180261. eCollection 2020.
Chondrosarcoma is primary bone cancer, with the forceful capacity to cause local invasion and distant metastasis, and has a poor prognosis. Cancer metastasis is a complication of most cancers; it is one of the leading causes of cancer-related death. Rhodomyrtone is a pure compound that has been shown to induce apoptosis and antimetastasis in skin cancer. However, the inhibitory effect of rhodomyrtone on human chondrosarcoma cell metastasis is largely unknown. Effect of rhodomyrtone on cell viability in SW1353 cell was determined by MTT assay. Antimigration, anti-invasion, and antiadhesion were carried out to investigate the antimetastatic potential of rhodomyrtone on SW1353 cells. Gelatin zymography was performed to determine matrix metalloproteinase-2 (MMP-2) and MMP-9 activities. The effect of rhodomyrtone on the underlying mechanisms was performed by Western blot analysis. The results demonstrated that rhodomyrtone reduced cell viability of SW1353 cells at the low concentration (<3 g/mL); cell viability was >80%. Rhodomyrtone at the subcytotoxic concentrations (0.5, 1.5, and 3 g/mL) significantly inhibited cell migration, invasion, and adhesion of SW1353 cells in a dose-dependent fashion. Protein expression of integrin , integrin 3, and the downstream migratory proteins including focal adhesion kinase (FAK) and the phosphorylation of serine/threonine AKT, Ras, RhoA, Rac1, and Cdc42 were inhibited after treatment with rhodomyrtone. Moreover, we found that rhodomyrtone decreased the protein level of MMP-2 and MMP-9 as well as the enzyme activity in SW1353 cells. Meanwhile, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression was increased in a dose-dependent fashion. Besides, rhodomyrtone dramatically inhibited the expression of growth factor receptor-bound protein-2 (GRB2) and the phosphorylated form of extracellular signal regulation kinase1/2 (ERK1/2) and c-Jun N-terminal kinase1/2 (JNK1/2). These results indicated that rhodomyrtone inhibited SW1353 cell migration, invasion, and metastasis by suppressing integrin 3/FAK/AKT/small Rho GTPases pathway as well as downregulation of MMP-2/9 via ERK and JNK signal inhibition. These findings indicate that rhodomyrtone possessed the antimetastasis activity that may be used for antimetastasis therapy in the future.
软骨肉瘤是原发性骨癌,具有强大的局部侵袭和远处转移能力,预后较差。癌症转移是大多数癌症的一种并发症,是癌症相关死亡的主要原因之一。玫红山楂素是一种纯化合物,已被证明可诱导皮肤癌细胞凋亡和抑制转移。然而,玫红山楂素对人软骨肉瘤细胞转移的抑制作用在很大程度上尚不清楚。通过MTT法测定玫红山楂素对SW1353细胞活力的影响。进行抗迁移、抗侵袭和抗黏附实验以研究玫红山楂素对SW1353细胞的抗转移潜力。采用明胶酶谱法测定基质金属蛋白酶-2(MMP-2)和MMP-9的活性。通过蛋白质印迹分析研究玫红山楂素对潜在机制的影响。结果表明,低浓度(<3μg/mL)的玫红山楂素可降低SW1353细胞的活力;细胞活力>80%。亚细胞毒性浓度(0.5、1.5和3μg/mL)的玫红山楂素以剂量依赖性方式显著抑制SW1353细胞的迁移、侵袭和黏附。用玫红山楂素处理后,整合素α3、整合素β3以及下游迁移蛋白包括粘着斑激酶(FAK)和丝氨酸/苏氨酸蛋白激酶AKT、Ras、RhoA、Rac1和Cdc42的磷酸化的蛋白表达受到抑制。此外,我们发现玫红山楂素降低了SW1353细胞中MMP-2和MMP-9的蛋白水平以及酶活性。同时,金属蛋白酶组织抑制剂-1(TIMP-1)和TIMP-2的表达呈剂量依赖性增加。此外,玫红山楂素显著抑制生长因子受体结合蛋白-2(GRB2)以及细胞外信号调节激酶1/2(ERK1/2)和c-Jun氨基末端激酶1/2(JNK1/2)的磷酸化形式的表达。这些结果表明,玫红山楂素通过抑制整合素β3/FAK/AKT/小Rho GTP酶途径以及通过ERK和JNK信号抑制下调MMP-2/9来抑制SW1353细胞的迁移、侵袭和转移。这些发现表明玫红山楂素具有抗转移活性,未来可能用于抗转移治疗。